NCI invests in study of failed cancer trials; Pharmacyclics advances PhIII for ibrutinib;

 @FierceBiotech: Hear from top execs at Janssen talk about drug R&D, industry's drug pipeline efforts. More | Follow @FierceBiotech

 @RyanMFierce: Biotech rattled as Q1 first-time VC deals plunge to 18-year low. News | Follow @RyanMFierce

> Finnish drugmaker Orion rallied on news of increased cashflow from partnerships. Article

> Fast-moving Pharmacyclics ($PCYC) wrapped up enrollment of a Phase III trial for its closely watched cancer drug ibrutinib, which the FDA has given "Breakthrough Therapy" status. Item

Medical Device News

 @FierceMedDev: Hamburg: FDA is a bargain for taxpayers. Story | Follow @FierceMedDev

 @DamianFierce: LabCorp is slimming down and diversifying to stay profitable in a tough testing market. More | Follow @DamianFierce

> Intuitive Surgical's Q1 soars, despite da Vinci robot lawsuits. Article

> Covidien recalls ventilator batteries over failure risk. More

> Device company VC funding continues its plunge. Report

Pharma News

 @FiercePharma: U.K. likely to pay for Avastin despite another NICE rejection. More | Follow @FiercePharma

 @EricPFierce: Some popular drugs like Pradaxa, Prolia to be put through despised German price shredding formula. Story | Follow @EricPFierce

> Russia tells Abbott no-go on buyout of partner Petrovax. Article

> U.K. goes after GSK for decade-old pay-for-delay deal. Story

And Finally… The NCI is investing in a study of "exceptional responders" from failed cancer drug trials to learn why those patients benefited. Article